Navigation Links
Lifesaving HIV treatment could reach millions more people following landmark study
Date:7/3/2013

Millions more people could get access to life-saving HIV drug therapy, following a landmark study led by Australian researchers based at the Kirby Institute at the University of New South Wales (UNSW).

The researchers have found a lower daily dose of an important HIV drug therapy is safe and as effective in suppressing the virus as the standard recommended dose.

The findings have been presented at the International AIDS Society Conference in Kuala Lumpur, Malaysia.

"This has the potential to affect the treatment of millions of HIV positive people," says UNSW Professor Sean Emery, the protocol chairperson of the study, known as ENCORE1 and Head of the Therapeutic and Vaccine Research Program at the Kirby Institute.

"A reduced daily dose should translate into a lower cost of treatment and permit more effective and efficient use of health care resources. Essentially, more people could receive this life-saving treatment for the same amount of funding."

HIV-positive people from 13 countries in Africa, Asia, Australia, Europe and Latin America took part in the trial. Half these people took two-thirds of the current standard daily dose of the antiretroviral (ART) efavirenz, a commonly used treatment for HIV; the other half took the standard daily dose. The 630 participants were observed regularly for a year. The results indicate that a reduction in daily dose of one third is both safe and effective compared to the higher dose currently recommended for people with HIV infection.


'/>"/>

Contact: Laurie Legere
llegere@kirby.unsw.edu.au
61-413-476-647
University of New South Wales
Source:Eurekalert

Page: 1

Related biology news :

1. Continued research needed on treatment for women with lung cancer who are never smokers
2. Artificial sweetener a potential treatment for Parkinsons disease
3. Posttraumatic stress disorder treatment: Genetic predictor of response to exposure therapy
4. Scientists identify potential drug target for treatment-resistant anemias
5. Neurochemical traffic signals may open new avenues for the treatment of schizophrenia
6. Addition of bevacizumab to initial treatment for brain tumors does not extend patients lives
7. Engineered stem cell advance points toward treatment for ALS
8. Using big data to identify prostate cancers and best treatments
9. First successful treatment of pediatric cerebral palsy with autologous cord blood
10. Cutting-edge bacteria research leads to more effective treatment of complex infections
11. Study identifies possible new acute leukemia marker, treatment target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... Scientists propose in Nature blocking ... Gaucher and maybe other lysosomal storage diseases as a ... current therapies. An international research team led ... also included investigators from the University of Lübeck in ... 22. The study was conducted in mouse models of ...
(Date:2/22/2017)... Yorba Linda, Ca (PRWEB) , ... February 22, ... ... interactive virtual events for tech innovators, engineers, and scientists from around the world, ... event will place on February 22 and 23, 2017. This premier, online-only conference ...
(Date:2/22/2017)... , Feb. 22, 2017 Origin (Origin Agritech, LLC, a ... and seed provider, and Arcadia (Arcadia Biosciences, ... develops and commercializes agricultural productivity traits and nutritional products, today announced ... biotechnology product developed in China to ... trials. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech consulting ... European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings ... after more than a decade with leading market research firm, GfK. He began ...
Breaking Biology Technology: